NeoStem
420 Lexington Avenue
Suite 350
New York, New York 10170
Telephone: 1.212.584.4180

Research & Development Overview

NeoStem, a biopharmaceutical company developing novel cell based personalized medicine therapies, has a robust, diversified pipeline based on proprietary technologies. We invite you to learn more about our investigational cell therapeutics and future development of these technologies.


 TargetedCancer1

Metastatic melanoma

Targeting cancer initiating cells

NeoStem is developing an immunotherapeutic applicable across multiple solid tumors with Special Protocol Assessment, Fast Track and Orphan Drug designations for a Phase 3 program in metastatic melanoma and near-term development milestones.

Learn More


 IschemicRepair1

Acute myocardial infarction – STEMI

Enhancing the body’s healing response

NeoStem is developing a cell therapeutic applicable for multiple cardiovascular indications with an ongoing Phase 2 study for acute myocardial infarction.

Learn More


 ImmuneModulation1

Type 1 diabetes

Rebalancing the immune system

NeoStem is developing an immunomodulation therapeutic platform targeting type 1 diabetes and other autoimmune disorders.

Learn More


NeoStem - Cell Therapy Development - Clinical